EC Number   |
Application |
Reference |
|---|
   3.4.21.59 | drug development |
beta-tryptases are the major focus of drug development for therapeutic inhibition |
680108 |
| 3.4.21.59 | medicine |
development of tryptase inhibitors for the treatment of asthma |
652996 |
| 3.4.21.59 | medicine |
heparin antagonists potentially may be used in treatment of mast cell-mediated diseases, potent and selective inhibitor of tryptase will be an essential tool to determine the role of tryptase in inflammation and other processes, tryptase plays a role in asthma and other allergic and inflammatory skin diseases like psoriasis and atopic dermatitis |
650078 |
| 3.4.21.59 | medicine |
important in bacterial infections of the lung |
652145 |
| 3.4.21.59 | medicine |
increased tryptase concentrations are a risk marker for the severity of reactions to Hymenoptera stings or venom immunotherapy |
732170 |
| 3.4.21.59 | medicine |
mast cell tryptase can be an indicator of type I hypersensitivity reaction and thus may serve as a surrogate marker of anaphylaxis |
709767 |
| 3.4.21.59 | medicine |
potent and selective inhibitor of tryptase will be an essential tool to determine the role of tryptase in inflammation and other processes, tryptase plays a role in asthma and other allergic and inflammatory skin diseases like psoriasis and atopic dermatitis |
649421, 650825, 651932, 652713, 653333, 653618, 653635 |
| 3.4.21.59 | medicine |
serum mast cell tryptase level is significantly increased in untreated patients with mastocytosis |
697722 |
| 3.4.21.59 | medicine |
the concomitant presence of systemic reactions (especially anaphylaxis) after Hymenoptera stings and increased serum baseline tryptase levels strongly suggests that a bone marrow examination is indicated for the diagnosis of clonal mast cell disease |
698446 |
| 3.4.21.59 | medicine |
the number of both tryptase- and cathepsin-G-positive mast cells is significantly higher in cutaneous mastocytosis as compared to normal skin |
697086 |
